JP2016513704A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513704A5
JP2016513704A5 JP2016502487A JP2016502487A JP2016513704A5 JP 2016513704 A5 JP2016513704 A5 JP 2016513704A5 JP 2016502487 A JP2016502487 A JP 2016502487A JP 2016502487 A JP2016502487 A JP 2016502487A JP 2016513704 A5 JP2016513704 A5 JP 2016513704A5
Authority
JP
Japan
Prior art keywords
group
peak positions
crystalline
powder
ray diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016502487A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513704A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/027591 external-priority patent/WO2014152663A1/en
Publication of JP2016513704A publication Critical patent/JP2016513704A/ja
Publication of JP2016513704A5 publication Critical patent/JP2016513704A5/ja
Pending legal-status Critical Current

Links

JP2016502487A 2013-03-15 2014-03-14 チロシンキナーゼ阻害薬の結晶形態物及びその塩 Pending JP2016513704A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361801112P 2013-03-15 2013-03-15
US61/801,112 2013-03-15
PCT/US2014/027591 WO2014152663A1 (en) 2013-03-15 2014-03-14 Crystalline forms of tyrosine kinase inhibitors and their salts

Publications (2)

Publication Number Publication Date
JP2016513704A JP2016513704A (ja) 2016-05-16
JP2016513704A5 true JP2016513704A5 (https=) 2017-04-13

Family

ID=51529961

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502487A Pending JP2016513704A (ja) 2013-03-15 2014-03-14 チロシンキナーゼ阻害薬の結晶形態物及びその塩

Country Status (23)

Country Link
US (5) US8999992B2 (https=)
EP (1) EP2970148A4 (https=)
JP (1) JP2016513704A (https=)
KR (1) KR20150142688A (https=)
CN (1) CN105377821A (https=)
AU (1) AU2014239254B2 (https=)
BR (1) BR112015022631A2 (https=)
CA (1) CA2904403A1 (https=)
CL (1) CL2015002593A1 (https=)
CR (1) CR20150560A (https=)
EA (1) EA201591684A1 (https=)
GT (1) GT201500292A (https=)
HK (1) HK1220193A1 (https=)
MX (1) MX2015012403A (https=)
NI (1) NI201500139A (https=)
PE (1) PE20151884A1 (https=)
PH (1) PH12015502110A1 (https=)
SG (2) SG10201707484UA (https=)
SV (1) SV2015005074A (https=)
TN (1) TN2015000407A1 (https=)
UA (1) UA116466C2 (https=)
WO (1) WO2014152663A1 (https=)
ZA (1) ZA201507154B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5752601B2 (ja) 2008-12-08 2015-07-22 ブイエム ファーマ エルエルシー タンパク質受容体チロシンキナーゼ阻害薬の組成物
US8999992B2 (en) * 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
AU2015318324A1 (en) 2014-09-17 2017-04-06 Mundipharma International Corporation Limited Crystalline forms of tyrosine kinase inhibitors and their salts
US20180370926A1 (en) * 2015-08-07 2018-12-27 Purdue Pharma L.P. Process of preparing tyrosine kinase inhibitor
KR102717072B1 (ko) 2017-10-18 2024-10-15 인사이트 코포레이션 Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체
WO2019159097A1 (en) * 2018-02-14 2019-08-22 Sun Pharmaceutical Industries Limited Crystalline polymorphic forms of acalabrutinib
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1062357A (en) * 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
US4337341A (en) * 1976-11-02 1982-06-29 Eli Lilly And Company 4a-Aryl-octahydro-1H-2-pyrindines
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
RU2065438C1 (ru) 1993-12-22 1996-08-20 Институт химии природного органического сырья СО РАН Способ получения производных 3-фенилокси-5-гидроксиантра (1,9-cd)-изоксазол-6-она
US6635626B1 (en) 1997-08-25 2003-10-21 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
US5998463A (en) 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
US6476032B2 (en) 1998-12-17 2002-11-05 Wyeth 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)one derivatives
AU5179000A (en) 1999-06-03 2000-12-28 Basf Aktiengesellschaft Benzothiazinone and benzoxazinone compounds
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
EP1430053B1 (en) 2001-09-27 2006-10-25 SmithKline Beecham Corporation AZAOXOINDOLE DERIVATIVES AS Trk PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND CHRONIC PAIN
KR20030095729A (ko) 2002-06-14 2003-12-24 크리스탈지노믹스(주) 2-[5-(3-카복시-4-클로로-페닐)-푸란-2-일메틸렌]-3-옥소-2,3-디하이드로-5H-티아졸로[3,2-a]피리미딘-6-카복실산에틸 에스테르 유도체를 포함하는 단백질 티로신포스파타제 1B 활성 억제용 약학 조성물
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
ZA200502612B (en) 2002-10-08 2007-07-25 Rinat Neuroscience Corp Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
IL154370A0 (en) * 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
JP4733023B2 (ja) 2003-04-16 2011-07-27 ブリストル−マイヤーズ スクイブ カンパニー C型肝炎ウイルスの大環状イソキノリンペプチド阻害剤
EP1663962A4 (en) 2003-08-22 2007-08-22 Dendreon Corp COMPOSITIONS AND METHODS FOR TREATING A DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION
WO2008021463A2 (en) 2006-08-15 2008-02-21 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
EP3372614B1 (en) 2004-04-07 2022-06-08 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
WO2006007864A1 (en) 2004-07-17 2006-01-26 Max Planck Geselllschaft Zur Förderung Der Wissenschaft Treating neurodegenerative conditions
US7671077B2 (en) * 2004-07-19 2010-03-02 Leu-Fen Hou Lin Neuroprotective small organic molecules, compositions and uses related thereto
US7718674B2 (en) 2004-09-27 2010-05-18 Bridge Pharma, Inc. Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine
US7820668B2 (en) 2005-01-19 2010-10-26 Eisai Inc. Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP
FR2881138B1 (fr) 2005-01-27 2007-03-02 Servier Lab Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20060257337A1 (en) 2005-04-28 2006-11-16 David Sherris Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
JP5191155B2 (ja) 2006-03-27 2013-04-24 大塚製薬株式会社 カルボスチリル化合物からなる医薬
JP2007303392A (ja) 2006-05-11 2007-11-22 Honda Motor Co Ltd 気体燃料内燃機関の制御装置
WO2008053863A1 (en) 2006-10-30 2008-05-08 Santen Pharmaceutical Co., Ltd. Novel compound having 1,4-benzothiazin-3-one skeleton or 3,4-dihydroquinolin-2-one skeleton
CA2672860C (en) 2006-12-28 2013-01-29 Abbott Laboratories Inhibitors of poly(adp-ribose)polymerase
EP2218713A1 (en) 2007-08-17 2010-08-18 Hetero Drugs Limited Erlotinib hydrochloride polymorph Form A substantially free of polymorph Form B
JP5662801B2 (ja) 2007-11-16 2015-02-04 ホリンワース ファンド,エル.エル.シー. フィルタ設計方法およびメタマテリアル構造ベースのフィルタ
JP5752601B2 (ja) 2008-12-08 2015-07-22 ブイエム ファーマ エルエルシー タンパク質受容体チロシンキナーゼ阻害薬の組成物
EP2239256A1 (en) * 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
US8853235B2 (en) * 2009-11-23 2014-10-07 Senhwa Biosciences, Inc. Polymorphs and salts of a kinase inhibitor
US20130158264A1 (en) 2010-06-23 2013-06-20 Arlindo L. Castelhano Polymorphs of OSI-906
ES2637113T3 (es) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
WO2012119079A1 (en) 2011-03-03 2012-09-07 Indiana University Research And Technology Corporation uPAR-uPA INTERACTION INHIBITORS AND METHODS FOR TREATING CANCER
US8999992B2 (en) 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
AU2015318324A1 (en) 2014-09-17 2017-04-06 Mundipharma International Corporation Limited Crystalline forms of tyrosine kinase inhibitors and their salts

Similar Documents

Publication Publication Date Title
JP2016513704A5 (https=)
JP2018515490A5 (https=)
RU2014151565A (ru) Способ получения n-[5-(3,5-дифторбензил)-1н-индазол-3-ил]-4-(4-метилпиперазин-1-ил)-2-(тетрагидропиран-4-иламино)бензамида
JP2022058395A5 (https=)
JP2016528179A5 (https=)
JP2015512942A5 (https=)
JP2014524476A5 (https=)
CA2543650A1 (en) A crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same
RU2019101220A (ru) Кристаллические формы соединения триазолопиримидина
JP2018531280A5 (https=)
JP2013237682A5 (https=)
HRP20201383T1 (hr) Kruti oblici spoja za moduliranje kinaza
JP2011126896A5 (https=)
JP2017527578A5 (https=)
JP2013522232A5 (https=)
JP2010518110A5 (https=)
JP2009537498A5 (https=)
JP2016503010A5 (https=)
JP2016539985A5 (https=)
JP2018534289A5 (https=)
JP2019527239A5 (https=)
JP2019516749A5 (https=)
RU2020111019A (ru) Полиморфная форма tg02
JP2018524342A5 (https=)
JP2016510768A5 (https=)